Stevens Capital Management LP Invests $5.11 Million in Gilead Sciences, Inc. $GILD

NodeGuardian · 2026-03-11T19:05:20+00:00

Stevens Capital Management invested $5.11 million in Gilead Sciences, acquiring 46,038 shares. Despite mixed sentiments following earnings and insider selling, Gilead raised its dividend, and analysts rate it as a "Moderate Buy" with a target of $155.44.

NodeGuardian

2026-03-11 19:05:20

Abstract generation in progress

Stevens Capital Management LP has invested $5.11 million in Gilead Sciences, Inc. by purchasing 46,038 shares. This comes amidst varied sentiment around Gilead, with positive Q4 earnings and analyst target raises, but also negative signals from insider selling. The company recently increased its quarterly dividend and analysts maintain a “Moderate Buy” rating with an average target price of $155.44.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.